Merck and Eisai's Lenvima failed a Keytruda combo trial in newly diagnosed lung cancer. Johnson & Johnson and Legend Biotech's CAR-T posted a long tail to disease progression. AstraZeneca and Samsung Biologics included AZ's COVID antibody in their contract manufacturing deal. And more.
Regor Therapeutics Announces Completion of $90 Million Series B Financing
News provided by
Share this article
Share this article
SHANGHAI, Feb. 18, 2021 /PRNewswire/ Regor Therapeutics, a clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic diseases, announces the successful completion of $90 million Series B financing.
Founded in July of 2018 by a group of veteran drug hunters with extensive research and executive leadership experiences at top multinational pharmaceutical companies, Regor aims to establish world-class innovation capabilities and is committed to delivering clinically differentiated, best- and first-in-class drugs to serve patients globally. By leveraging CARD, Computer Accelerated Rational Discovery, a proprietary enabling technology platform, the team has successfully advanced numerous discovery programs in a dramatically accelerated fashion, including from ideas to a clinica
Regor Therapeutics Announces Completion of $90 Million Series B Financing apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.